Fig. 4From: Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16)A Comparison of OS in patients with c-kit mutations according GO treatment. B Comparison of CIR in patients with c-kit mutations according GO treatment. C Comparison of OS in patients without c-kit mutations according GO treatment. D Comparison of CIR in patients without c-kit mutations according GO treatmentBack to article page